Evidence map›Paper›PMID 26352162›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2015

TSP-1 Deficiency Alters Ocular Microbiota: Implications for Sjögren's Syndrome Pathogenesis.

Marielle Terzulli, Laura Contreras-Ruiz, Laura Contreras Ruiz, Abirami Kugadas, Sharmila Masli, Mihaela Gadjeva

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Insights into Microbiota in Sjögren's Syndrome.Medicina (Kaunas, Lithuania) · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Mouse Models of Sjögren's Syndrome with Ocular Surface Disease.International journal of molecular sciences · 2020
    Review
  10. Review
  11. The microbiome and ophthalmic disease.Experimental biology and medicine (Maywood, N.J.) · 2019
    Review
  12. Article
  13. Review
  14. Impact of Microbiome on Ocular Health.The ocular surface · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marielle Terzulli1 Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA.
Laura Contreras-Ruiz2 Department of Ophthalmology, Boston University , School of Medicine, Boston, MA.
Laura Contreras Ruiz
Abirami Kugadas1 Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA.
Sharmila Masli2 Department of Ophthalmology, Boston University , School of Medicine, Boston, MA.
Mihaela Gadjeva1 Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA.
Boston University · USHarvard University · USBrigham and Women's Hospital · US

Funding

Molecular Mechanisms Underlying Immune Regulation of Ocular InflammationR01EY015472 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI MASLI, SHARMILA · 2004 to 2013
$4.3M
Novel treatment strategies to regulate inflammation during P.aeruginosa keratitisR01EY022054 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI GADJEVA, MIHAELA GUEORGUIEVA · 2012 to 2020
$4.0M
NEI NIH HHS EY015472NEI NIH HHS EY022054NEI NIH HHS R01 EY022054
6 · The paper itself

Abstract

purposeThe potential role of commensals as triggering factors that promote inflammation in dry eye disease has not been explored. The objective of this study was to evaluate whether ocular microbiota changes with the onset of dry eye disease in thrombospondin-1-deficient (TSP-1(-/-)) mice, a strain that develops Sjögren's syndrome-like disease.

methodsConjunctival swabs were collected from TSP-1(-/-) and C57BL/6 mice and analyzed for bacterial presence. Opsonophagocytosis of the bacterial conjunctival isolates derived from the aged TSP-1(-/-) mice by neutrophils derived from either TSP-1(-/-) or C57BL/6 bone marrow was evaluated. The bactericidal activities of TSP-1-derived peptide were examined.

resultsWe found that in TSP-1(-/-) mice, the conjunctival colonization with Staphylococcus aureus and coagulase negative staphylococci sp (CNS) species was significantly increased with aging and preceded that of the wild-type C57BL/6 control mice. This correlated with increased neutrophil infiltration into the conjunctiva of the TSP-1(-/-) mice, suggesting that TSP-1 plays a significant role in regulating immunity to commensals. Accordingly, the TSP-1(-/-) PMNs opsonophagocytozed the ocular commensals less efficiently than the TSP-1-sufficient neutrophils. Furthermore, a TSP-1-derived peptide, 4N1K, exhibited significant antimicrobial activity when compared to a control peptide against commensal sp.

conclusionThese studies illustrate that alterations in the commensal frequency occur in the early stages of development of Sjögren's-like pathology and suggest that interventions that limit commensal outgrowth such as the use of TSP-1-derived peptides could be used for treatment during the early stages of the disease to reduce the commensal burden and ensuing inflammation.

Indexed as

MicrobiotaAnimalsDisease Models, AnimalEnzyme-Linked Immunosorbent AssayEyeInflammationMaleMiceMice, Inbred C57BLMice, TransgenicSjogren's SyndromeStaphylococcus aureusThrombospondin 1Thbs1 protein, mouseThrombospondin 1

Identifiers

PMID26352162
PMCPMC4575514
OpenAlexW1944941250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.